1. Home
  2. KRYS vs HSIC Comparison

KRYS vs HSIC Comparison

Compare KRYS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$340.21

Market Cap

10.3B

Sector

Health Care

ML Signal

HOLD

Logo Henry Schein Inc.

HSIC

Henry Schein Inc.

HOLD

Current Price

$80.10

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRYS
HSIC
Founded
2015
1932
Country
United States
United States
Employees
295
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
8.7B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
KRYS
HSIC
Price
$340.21
$80.10
Analyst Decision
Strong Buy
Buy
Analyst Count
11
16
Target Price
$297.60
$85.07
AVG Volume (30 Days)
294.7K
1.3M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
128.00
7.21
EPS
1.83
0.92
Revenue
$389,130,000.00
$13,201,995,000.00
Revenue This Year
$38.74
$6.12
Revenue Next Year
$32.53
$3.64
P/E Ratio
$187.67
$85.51
Revenue Growth
33.94
5.94
52 Week Low
$130.50
$61.97
52 Week High
$356.50
$89.29

Technical Indicators

Market Signals
Indicator
KRYS
HSIC
Relative Strength Index (RSI) 65.25 60.70
Support Level $253.89 $75.18
Resistance Level N/A $80.37
Average True Range (ATR) 12.77 1.77
MACD 2.68 0.04
Stochastic Oscillator 72.67 67.39

Price Performance

Historical Comparison
KRYS
HSIC

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.

Share on Social Networks: